Document 0211
 DOCN  M9550211
 TI    HIV vaccine development and clinical trials.
 DT    9505
 AU    Hoff R; McNamara J; Fowler M; McCauley M; Division of AIDS, National
       Institute of Allergy and Infectious; Diseases, National Institutes of
       Health, Bethesda, MD.
 SO    Acta Paediatr Suppl. 1994 Aug;400:73-7. Unique Identifier : AIDSLINE
       MED/95135025
 AB    The magnitude of HIV pandemic has made the development of HIV vaccines
       an urgent biomedical research priority. Although the biologic problems
       in designing a vaccine for a chronic viral infection like HIV are
       formidable, there has been encouraging progress. More than a dozen first
       generation prophylactic HIV vaccine candidates have completed phase I
       human trials that have established the safety and immunogenicity of
       these products in adults. A phase II trial of two HIV subunit envelope
       vaccines in adults at high risk of HIV infection is underway in the
       United States, and preparations for phase III efficacy trials have
       begun. Preliminary studies are under way to evaluate the potential
       application of active and passive immunization for preventing vertical
       transmission of HIV. Because of the higher rate of HIV transmission and
       a more abbreviated time course to disease, it may be more efficient to
       evaluate the efficacy of HIV vaccines in HIV infected pregnant women and
       their offspring than in adults who are exposed sexually to HIV.
 DE    Adult  *AIDS Vaccines  Clinical Trials  Disease Transmission, Vertical
       Female  Human  HIV Infections/*PREVENTION & CONTROL/TRANSMISSION
       Infant, Newborn  Pregnancy  Pregnancy Complications,
       Infectious/*PREVENTION & CONTROL  Risk Factors  Treatment Outcome
       *Vaccination  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).